Clinical trialNCT06075953RecruitingPhase 2Interventional

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

SponsorQuantumLeap Healthcare CollaborativeEnrollment400Ductal Carcinoma in Situ

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the option to continue on the treatment. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to provide blood sample to understand their immune status, provide saliva sample for genetic testing, provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

(Co-PI) Kelly Hewitt, MD, FACS
Huntsman Cancer Institute at the University of Utah
Principal Investigator
clinicaltrials.gov ↗
Laura Esserman, MD, MBA
University of California, San Fancisco - Department of Surgery
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

28 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Berkeley Outpatient Center
Berkeley, California, United States
Jordan Jackson, MD
Recruiting
City of Hope -Duarte Cancer Center
Duarte, California, United States
Jennifer Tseng, MD
Recruiting
City of Hope - Lennar Foundation Cancer Center
Irvine, California, United States
Jennifer Tseng, MD
Recruiting
Ucla
Los Angeles, California, United States
Mediget Teshome, MD
Recruiting
Ucsf
San Francisco, California, United States
Jordan Jackson, MD
Recruiting
City of Hope
South Pasadena, California, United States
Jennifer Tseng, MD
Recruiting
John Muir Health
Walnut Creek, California, United States
Monica Eigelberger, MD
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Laura Kruper, MD
Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
Clara Farley, MD
Recruiting
University of Chicago Medical Center
Chicago, Illinois, United States
Betty Fan, MD
Recruiting
Maple Grove Cancer Center
Maple Grove, Minnesota, United States
Jane Hui, MD
Recruiting
Hennepin Healthcare -Minneapolis
Minneapolis, Minnesota, United States
Satya Bommakanti, MD
Recruiting
University of Minnesota
Minneapolis, Minnesota, United States
Jane Hui, MD
Recruiting
Health Partners - Frauenshuh Cancer Center
Saint Louis Park, Minnesota, United States
Rachel Lerner, MD
Recruiting
Health Partners - Regions Hospital
Saint Paul, Minnesota, United States
Rachel Lerner, MD
Recruiting
Englewood Hospital and Medical Center
Englewood, New Jersey, United States
Jennifer Marti, MD
Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Tara Balija, MD
Recruiting
Mount Sinai Chelsea
New York, New York, United States
Tara Balija, MD
Recruiting
Mount Sinai Union Square
New York, New York, United States
Tara Balija, MD
Recruiting
Mount Sinai West
New York, New York, United States
Tara Balija, MD
Recruiting
Duke Cancer Institute
Durham, North Carolina, United States
Ton Wang, MD
Recruiting
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
Marissa Howard-McNatt, MD
Recruiting
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, United States
Active, not recruiting
Paoli Hospital
Paoli, Pennsylvania, United States
Active, not recruiting
Lankenau Medical Center
Wynnewood, Pennsylvania, United States
Active, not recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Ingrid Meszoely, MD
Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah, United States
Kirstyn Brownson, MD
Recruiting
Virginia Commonwealth University
Richmond, Virginia, United States
Kandace McGuire, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AnastrazoleElacestrant →Exemestane →Letrozole →Tamoxifen →Testosterone + AnastrazoleEndoxifen

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 17 Feb 2024
Primary completion: 30 Nov 2028
Completion: 30 Nov 2033
Last update posted: 21 Jul 2026
Registered enrollment: 400
Registry id: NCT06075953

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.